Amylyx Pharmaceuticals, Inc.
AMLX
शेयरों में रैंक
#4499
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
शेयर मूल्य
$27.25
अंतिम समन्वयन: 2026-10-19
मार्केट कैप
$3.42B
बदलाव (1 दिन)
3.45%
बदलाव (1 वर्ष)
77.29%
देश
US
व्यापार Amylyx Pharmaceuticals, Inc. (AMLX)
श्रेणी
Healthcare
Amylyx Pharmaceuticals, Inc. (AMLX) के लिए EPS
June 2026 TTM तक का EPS: $-1.41
Amylyx Pharmaceuticals, Inc. की नवीनतम वित्तीय रिपोर्टों और शेयर मूल्य के अनुसार, कंपनी का वर्तमान EPS (TTM) $-1.41 है। 2023 के अंत में, कंपनी का EPS $0.73 था, जो 2022 के EPS $-2.98 के की वृद्धि था।
Amylyx Pharmaceuticals, Inc. के लिए 2019 से 2026 तक का EPS इतिहास
प्रत्येक वर्ष के अंत में EPS
| वर्ष | EPS | परिवर्तन |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए EPS
| कंपनी | EPS | EPS अंतर | देश |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
